SUPN - Supernus Pharmaceuticals, Inc.
| Previous Close | 26.65 |
| Open | 26.97 |
| Bid | 24.00 x 800 |
| Ask | 0.00 x 1400 |
| Day's Range | 26.40 - 26.98 |
| 52 Week Range | 24.77 - 49.25 |
| Volume | 344,802 |
| Avg. Volume | 555,035 |
| Market Cap | 1.394B |
| Beta (3Y Monthly) | 1.42 |
| PE Ratio (TTM) | 13.70 |
| EPS (TTM) | 1.94 |
| Earnings Date | Nov 4, 2019 - Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 51.71 |
- Simply Wall St.
Estimating The Fair Value Of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Does the October share price for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reflect what it's really worth? Today...
- Simply Wall St.
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Insiders Increased Their Holdings
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
- GlobeNewswire
Supernus to Present at the 2019 Cantor Global Healthcare Conference
ROCKVILLE, Md., Sept. 25, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment.
- GuruFocus.com
5 Health Care Stocks Gurus Are Buying
Merit Medical Systems makes the list Continue reading...
- Simply Wall St.
How Does Investing In Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Impact The Volatility Of Your Portfolio?
Anyone researching Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) might want to consider the historical volatility of...
- TheStreet.com
There's Value In These 2 Small Beaten Down Biotech Stocks
The market continues to ebb and flow with the direction of trade tensions. Yesterday, markets rallied strongly on some encouraging remarks from the Chinese delegation about the prospects for further trade talks.
- GuruFocus.com
Supernus Pharmaceuticals Inc (SUPN) President, CEO Jack A. Khattar Bought $190,008 of Shares
President, CEO of Supernus Pharmaceuticals Inc (30-Year Financial, Insider Trades) Jack A. Khattar (insider trades) bought 7,200 shares of SUPN on 08/23/2019 at an average price of $26.39 a share. Continue reading...
- GlobeNewswire
Supernus to Present at Two September Healthcare Conferences
ROCKVILLE, Md., Aug. 26, 2019 -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
- Thomson Reuters StreetEvents
Edited Transcript of SUPN earnings conference call or presentation 7-Aug-19 1:00pm GMT
Q2 2019 Supernus Pharmaceuticals Inc Earnings Call
- Zacks
Can Value Investors Pick Supernus Pharmaceuticals (SUPN)?
Let's see if Supernus Pharmaceuticals (SUPN) stock is a good choice for value-oriented investors right now from multiple angles.
- Simply Wall St.
These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Safely
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Motley FoolSupernus Pharmaceuticals Inc (SUPN) Q2 2019 Earnings Call Transcript
SUPN earnings call for the period ending June 30, 2019.
- Zacks
Supernus Pharmaceuticals (SUPN) Q2 Earnings Top Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 8.93% and -3.70%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Supernus Announces Second Quarter 2019 Financial Results
Total revenue of $104.7 million, a 5.2% increase over 2018Net product sales of $102.4 million, a 5.5% increase over 2018Operating earnings of $42.6 million, a 19.3% increase.
- Simply Wall St.
Do Supernus Pharmaceuticals's (NASDAQ:SUPN) Earnings Warrant Your Attention?
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
- GlobeNewswire
Supernus to Host Second Quarter 2019 Earnings Conference Call
ROCKVILLE, Md., July 23, 2019 -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of.
- Zacks
4 Medical Stocks to Consider After Federal Judge Blocks Trump Proposal
In early May, President Donald Trump announced that he would be requiring Big Pharma to list the prices of their drugs in their TV advertisements.
- Markit
See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc NASDAQ NMS:SUPNView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding SUPN are favorable, with net inflows of $2.29 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Simply Wall St.
How Do Analysts See Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Performing Over The Next Year?
In March 2019, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) released its earnings update. Generally, analysts seem...
- Insider Monkey
Here’s What Hedge Funds Think About Supernus Pharmaceuticals Inc (SUPN)
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]
- Thomson Reuters StreetEvents
Edited Transcript of SUPN earnings conference call or presentation 8-May-19 1:00pm GMT
Q1 2019 Supernus Pharmaceuticals Inc Earnings Call
- Simply Wall St.
Read This Before You Buy Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Because Of Its P/E Ratio
The goal of this article is to teach you how to use price to earnings ratios (P/E ratios). To keep it practical, we'll...
